Skip to main content
  • ImmunoRx Pharma Inc.
  • Investment: 2021
  • Status: Active

ImmunoRx Pharma, Inc. plans to develop a first-in-class antibody, to proof-of-concept, with the potential to treat certain types of chronic inflammatory diseases, including ulcerative colitis, rheumatoid arthritis and Crohn’s disease.

This antibody targets a new critical target in chronic inflammation and auto-immunity which was originally discovered by Dr. Tessier based in Canada. More than 11 million people worldwide are affected by inflammatory bowel diseases (IBD), including ulcerative colitis and Crohn’s disease. Ulcerative colitis (UC) is a long-term condition that results in inflammation and ulcers of the colon and rectum.

Involved Team

Marc Rivière, MD
General Partner,

Caroline Fortier (CEO)